Body Vision Medical, a leader in AI-powered intraoperative imaging, has unveiled a major upgrade to its LungVision® platform, introducing universal access to its proprietary AI Tomo® imaging technology. This development allows AI Tomo to integrate with nearly any fluoroscopic C-arm model, making advanced 3D visualization accessible without the need for expensive 3D fluoroscopy systems. The innovation is aimed at improving early and accurate lung cancer diagnosis worldwide.
AI Tomo® technology reconstructs real-time 3D views from widely available 2D imaging systems during bronchoscopy procedures. This enables clinicians to detect and navigate toward even small lung lesions with greater precision, whether in manual or robotic-assisted interventions. The system also helps minimize CT-to-body divergence, a common challenge in lung navigation, thereby improving targeting accuracy while reducing radiation exposure for both patients and healthcare staff.
The universal compatibility of AI Tomo® means that healthcare providers across diverse settings—regardless of their existing imaging hardware—can benefit from advanced intraoperative guidance. According to Body Vision Medical CEO Matt Baker, this update empowers physicians to maximize diagnostic yields, enhance procedural confidence, and ensure better patient outcomes without requiring significant infrastructure changes.
By removing a major cost and technology barrier, Body Vision Medical is taking a significant step toward democratizing high-precision lung cancer diagnostics. This aligns with the growing global emphasis on early detection, minimally invasive procedures, and AI-driven medical imaging.
MedTech Summary:
Body Vision Medical’s LungVision® platform now offers universal AI Tomo® access for nearly all fluoroscopic C-arm models.
AI Tomo® generates real-time 3D views from standard 2D imaging, enhancing precision in bronchoscopy.
Upgrade improves global access to advanced lung cancer diagnostics without costly 3D imaging systems.
